Claudio Molinari

Prof. Claudio Molinari


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RGRebecca Galla
Rebecca Galla
SRSara Ruga
Sara Ruga
SASilvio Aprile
Silvio Aprile
SFSara Ferrari
Sara Ferrari
ABArianna Brovero
Arianna Brovero
Francesca UbertiFrancesca Uberti
Francesca Uberti
Background: In recent decades, hyaluronic acid (HA) has attracted great attention as a new treatment option for osteoarthritis. Classical therapies are not able to stop the cartilage degeneration process nor do they favor tissue repair. Nowadays, it is accepted that high molecular weight HA can reduce inflammation by promoting tissue regeneration; therefore, the aim of this study was to verify the efficacy of a new high molecular weight HA of plant origin (called GreenIuronic®) in maintaining joint homeostasis and preventing the harmful processes of osteoarthritis. Methods: The bioavailability of GreenIuronic® was investigated in a 3D intestinal barrier model that mimics human oral intake while excluding damage to the intestinal barrier. Furthermore, the chemical significance and biological properties of GreenIuronic® were investigated in conditions that simulate osteoarthritis. Results: Our data demonstrated that GreenIuronic® crosses the intestinal barrier without side effects as it has a chemical–biological profile, which could be responsible for many specific chondrocyte functions. Furthermore, in the osteoarthritis model, GreenIuronic® can modulate the molecular mechanism responsible for preventing and restoring the degradation of cartilage. Conclusion: According to our results, this new form of HA appears to be well absorbed and distributed to chondrocytes, preserving their biological activities. Therefore, the oral administration of GreenIuronic® in humans can be considered a valid strategy to obtain beneficial therapeutic effects during osteoarthritis.

22 February 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
Francesca UbertiFrancesca Uberti
Francesca Uberti
VMVera Morsanuto
Vera Morsanuto
SRSara Ruga
Sara Ruga
RGRebecca Galla
Rebecca Galla
MFMahitab farghali
Mahitab farghali
CMClaudio Molinari
Claudio Molinari
Background: Magnesium is involved in a wide variety of physiological processes including direct relaxation of smooth muscle. A magnesium imbalance can be considered the primary cause or consequence of many pathophysiological conditions. The smooth muscle tissue of the uterus, i.e., the myometrium, undergoes numerous physiological changes during life, fundamental for uterine activities, and it receives proven benefits from magnesium supplementation. However, magnesium supplements have poor absorption and bioavailability. Furthermore, no data are available on the direct interaction between intestinal absorption of magnesium and relaxation of the myometrium. Methods: Permeability in human intestinal cells (Caco-2 cells) and direct effects on myometrial cells (PHM1-41 cells) of two different forms of magnesium, i.e., sucrosomial and bisglycinate, were studied in order to verify the magnesium capacity of modulate contractility. Cell viability, reactive oxygen species (ROS) and nitric oxide (NO) production, magnesium concentration, contractility, and pathways involved were analyzed. Results: Data showed a better influence of buffered chelate bisglycinate on intestinal permeability and myometrial relaxation over time with a maximum effect at 3 h and greater availability compared to the sucrosomial form. Conclusions: Magnesium-buffered bisglycinate chelate showed better intestinal absorption and myometrial contraction, indicating a better chance of effectiveness in human applications.

Verified
Journal Article
Open access
PDF file
SRSara Ruga
Sara Ruga
RGRebecca Galla
Rebecca Galla
CPClaudia Penna
Claudia Penna
CMClaudio Molinari
Claudio Molinari
Francesca UbertiFrancesca Uberti
Francesca Uberti
Background: Hypercholesterolemia is a major cause of cardiovascular disease and statins, the HMGCoA inhibitors, are the most prescribed drugs. Statins reduce the production of hepatic cholesterol, leading to greater expression of the LDL receptor and greater absorption of circulating LDL, reducing peripheral LDL levels. Unfortunately, statins are believed to induce myopathy and other severe diseases. To overcome this problem, safe nutraceuticals with the same activity as statins could hold great promise in the prevention and treatment of hypercholesterolemia. In this study, the anti-cholesterol efficacy of a new nutraceutical, called Esterol10®, was evaluated. Methods: HepG2 cells were used to study the biological mechanisms exerted by Esterol10® analyzing different processes involved in cholesterol metabolism, also comparing data with Atorvastatin. Results: Our results indicate that Esterol10® leads to a reduction in total hepatocyte cholesterol and an improvement in the biosynthesis of free cholesterol and bile acids. Furthermore, the anti-cholesterol activity of Esterol10® was also confirmed by the modulation of the LDL receptor and by the accumulation of lipids, as well as by the main intracellular pathways involved in the metabolism of cholesterol. Conclusions: Esterol10® is safe and effective with anti-cholesterol activity, potentially providing an alternative therapy to those based on statins for hypercholesterolemia disease.

Verified
Journal Article
Open access
PDF file
SMSimone Mulè
Simone Mulè
GRGiorgia Rosso
Giorgia Rosso
MBMattia Botta
Mattia Botta
ABArianna Brovero
Arianna Brovero
SFSara Ferrari
Sara Ferrari
Francesca UbertiFrancesca Uberti
Francesca Uberti
Neuropathy affects 7–10% of the general population and is caused by a lesion or disease of the somatosensory system. The limitations of current therapies highlight the necessity of a new innovative approach to treating neuropathic pain (NP) based on the close correlation between oxidative stress, inflammatory process, and antioxidant action. The advantageous outcomes of a novel combination composed of Hop extract, Propolis, Ginkgo Biloba, Vitamin B, and palmitoylethanolamide (PEA) used as a treatment was evaluated in this study. To assess the absorption and biodistribution of the combination, its bioavailability was first examined in a 3D intestinal barrier model that replicated intestinal absorption. Further, a 3D nerve tissue model was developed to study the biological impacts of the combination during the essential pathways involved in NP. Our findings show that the combination could cross the intestinal barrier and reach the peripheral nervous system, where it modulates the oxidative stress, inflammation levels, and myelination mechanism (increased NRG, MPZ, ERB, and p75 levels) under Schwann cells damaging. This study proves the effectiveness of Ginkgo Biloba, Propolis, Hop extract, Vitamin B, and PEA in avoiding nerve damage and suggests a potential alternative nutraceutical treatment for NP and neuropathies.

Verified
Journal Article
Open access
PDF file
RGRebecca Galla
Rebecca Galla
SMSimone Mulè
Simone Mulè
SFSara Ferrari
Sara Ferrari
CGChiara Grigolon
Chiara Grigolon
CMClaudio Molinari
Claudio Molinari
Francesca UbertiFrancesca Uberti
Francesca Uberti
Palmitoylethanolamide (PEA) is a highly lipophilic molecule with low solubility, making absorption difficult. Recent techniques like micronisation, ultra-micronisation and combining PEA with solvents have improved their bioavailability and stability. Our study analysed particle size differences and absorption kinetics using specific solvents (PEAΩ and PEA DynoΩ) over time (0.5 h–6 h) in a dose-dependent manner (200 mg–1800 mg). The results showed that PEAΩ and PEA DynoΩ achieved 82–63% absorption at 3 h, compared to 30–60% for micronised, ultra-micronised PEA and a commercial product, highlighting the optimal dose range of 300 mg–600 mg. In addition, a 3D model of the peripheral nerve was utilised to explain the efficacy after gut passage and support the most effective dose (300 mg or 600 mg) achieved at the gut level. PEAΩ and PEA DynoΩ, which are associated with better intestinal bioavailability compared to PEA-micronised, PEA ultra-micronised and a commercial product, have allowed not only a reduction in the inflammatory context but also an improvement of peripheral nerve well-being by increasing specific markers like MPZ (26–36% vs. 8–15%), p75 (25–32% vs. 13–16%) and NRG1 (22–29.5% vs. 11–14%). These results highlight the potential of advanced PEA formulations to overcome solubility challenges and maintain in vitro efficacy, modulating peripheral nerve well-being.

15 April 2025 in Foods
Verified
Journal Article
Open access
PDF file
RGRebecca Galla
Rebecca Galla
SMSimone Mulè
Simone Mulè
SFSara Ferrari
Sara Ferrari
FPFrancesca Parini
Francesca Parini
AGAnnalisa Givonetti
Annalisa Givonetti
Francesca UbertiFrancesca Uberti
Francesca Uberti
Tremella fuciformis is high in polysaccharides, which have a structure made up of a straight chain of (1→3) α-D-mannan and side chains of glucuronic acid, xylose, and fucose. This study aimed to evaluate whether the non-animal hyaluronic acid extracted from Tremella fuciformis can maintain the chemical and physical characteristics of hyaluronic acid that ensure its biological functionality. Chemical and physical analyses such as hyaluronic content, screening of metals, purity, pH, nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (ATR/FTIR), and MALDI-TOF were performed. Chemical characterisation revealed that the most abundant polysaccharide in the extract was hyaluronic acid, accounting for ca. 87.76%, with a molecular weight above 2000 kDa. In addition, ATR/FTIR and NMR spectroscopy and MALDI-TOF analysis confirmed that Tremella fuciformis extract is a source of non-animal hyaluronic acid. In summary, every molecular attribute examined played a significant role in determining the functional qualities of the extract, indicating that a thoughtful choice of extraction technique can enhance its advantages.